NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Quimbaya Gold Inc. (CSE: QIM,OTC:QIMGF) (OTCQB: QIMGF) (FSE: K05) (‘Quimbaya’ or the ‘Company’) announces that Denarius Metals Corp. has elected …
Category:
Investing
-
-
Investing
Harvest Gold Announces Closing of Non-Brokered Private Placement with Crescat Capital as Lead Investor
by admin(TheNewswire) Vancouver, British Columbia TheNewswire – August 1, 2025 ‑ Harvest Gold Corporation (TSXV: HVG,OTC:HVGDF) (‘ Harvest Gold ‘ or the ‘ Company ‘) announces that, subject to the …
-
-
The US Federal Reserve held its fifth meeting of 2025 from Tuesday (July 29) to Wednesday (July 30) against a backdrop of trade tensions, spurred on by the Trump administration’s tariffs. The central bank met …
-
The psychedelic drugs market is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, …
-
Investing
SAGA Metals Completes Strategic Infrastructure Upgrades in Preparation for Major Drill Program at the 100% Owned Radar Titanium Property in Labrador, Canada
by adminSaga Metals Corp. (‘SAGA’ or the ‘Company’) (TSXV: SAGA,OTC:SAGMF) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company focused on critical mineral discovery, is pleased to announce SAGA’s team has completed the 4 km …
-
Investing
Skyharbour Expands Uranium Exploration Portfolio to Over 616,000 Hectares Across Thirty-Seven Projects in the Athabasca Basin, Northern Saskatchewan
by adminSkyharbour Resources Ltd . (TSX-V: SYH ) (OTCQX: SYHBF ) (Frankfurt: SC1P ) (‘Skyharbour’ or the ‘Company’), is pleased to announce that it has acquired, through inexpensive online staking, 21 new prospective uranium exploration …
-
-
-
Investing
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart
by adminLu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25 …